CABA insider trading
NasdaqGS HealthcareCabaletta Bio, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Company website: www.cabalettabio.com
CABA insider activity at a glance
FilingIQ has scored 65 insider transactions for CABA since Oct 29, 2019. The most recent filing in our index is dated Mar 2, 2026.
Across the full history, 17 open-market purchases
and 25 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CABA insider trades is 57.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Top insiders trading CABA
13F funds holding CABA
Frequently asked
- How many insider trades does FilingIQ track for CABA?
- FilingIQ tracks 65 Form 4 insider transactions for CABA (Cabaletta Bio, Inc.), covering filings from Oct 29, 2019 onwards. 6 of those were filed in the last 90 days.
- Are CABA insiders net buyers or net sellers?
- Across the full Form 4 history for CABA, 17 transactions (26%) were open-market purchases and 25 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CABA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CABA in?
- Cabaletta Bio, Inc. (CABA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $317.68M.
Methodology & sources
Every CABA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.